Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

PHASE1/PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

July 31, 2001

Study Completion Date

June 30, 2004

Conditions

Esophageal CancerExtrahepatic Bile Duct CancerGastric CancerHead and Neck CancerLiver CancerUnspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

capecitabine

DRUG

carboplatin

DRUG

epirubicin hydrochloride

Trial Locations (3)

20889-5105

Center for Cancer Research, Bethesda

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

23708-2197

Naval Medical Center, Portsmouth, Portsmouth

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00021047 - Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor | Biotech Hunter | Biotech Hunter